Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179518 | 0.91 | S1PR1 (0.40) | KDM4EATMNPC1MAPK1VCP | |
| SCHEMBL1178939 | 0.90 | S1PR1 (0.37) | KDM4EATMNPC1MAPTKMT2A | |
| SCHEMBL1178755 | 0.89 | KDM4E (0.55) | KDM4EATMNPC1MAPK1VCP | |
| SCHEMBL1178798 | 0.85 | ESR1 (0.41) | KDM4EATMNPC1MAPK1VCP | |
| SCHEMBL1179093 | 0.81 | KDM4E (0.50) | KDM4EATMNPC1MAPK1KMT2A | |
| SCHEMBL1179044 | 0.81 | TP53 (0.36) | KDM4EATMNPC1MAPTS1PR1 | |
| SCHEMBL1179247 | 0.80 | KDM4E (0.46) | KDM4EATMNPC1MAPK1MAPT | |
| SCHEMBL1179385 | 0.79 | S1PR1 (0.39) | KDM4EATMNPC1MAPTS1PR1 | |
| SCHEMBL3084211 | 0.79 | S1PR1 (0.53) | S1PR1S1PR3 | |
| SCHEMBL3080626 | 0.79 | S1PR1 (0.53) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | claimed |
| EP-2262800-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-22 | — | — | EP | claimed |
| WO-2009109907-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | claimed |
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| EP-2262800-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009109907-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | TYMP, DPYD, ENTPD5 | KDM4E 1861/4885ATM 1361/4885NPC1 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.